Pdg22 a Decision Analysis of Adding Angiotensin Ii to Renal Replacement Therapy to Treat Patients With Acute Kidney Injury and Vasodilatory Shock

Abstract

immunotherapies with the most popular chemotherapy in Taiwan. The analysis was from the perspective of Taiwan national healthcare system perspective. We reconstructed individual patient data (IPD) from published clinical trials for overall survival (OS) and progression-free survival (PFS) using a validated algorithm. Costs were collected from Taiwan's National Health Insurance Research Databases and a medical center. Published utility values associated with each of the health states were used. 3% discount rate was applied to all the costs. Results: Base case results show that patients treated with immunotherapies were associated with higher costs and higher survival times. The mean costs of docetaxel、nivolumab、pembrolizumab、atezo-

The Use of Angiotensin II for the Treatment of Post-cardiopulmonary Bypass Vasoplegia

“…Therefore, the results from this recent post hoc analysis suggest that the majority of patients with catecholamine-resistant vasodilatory shock suffer from a malfunctioned RAAS and, additionally, that plasma renin concentration measurements could develop into an innovative approach that will help physicians to detect patients who might benefit from AII infusions. Another post hoc analysis confirmed the cost-effectiveness of including Giapreza in the treatment of vasodilatory shock in ICUs of US hospital [40], while Anyanwu et al [41] concluded that, specifically in AKI patients, even though the costs increase with the addition of AII in the standard vasopressor regime ($8657 (AII) vs $6517 (standard of care)), the increasing costs of RRT diminish the cost-difference between the two treatments.…”